Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Narcotic Pain (Oct 2016)

Posted by Matt Breese on Oct 12, 2016

Find me on:

According to our recent payer coverage analysis for narcotic pain treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A market access snapshot for narcotic pain treatments shows an increase in PA and step therapy policies across most channels, but most apparent for commercial formularies. While PAs are more common, step therapies are particularly restrictive for branded products, with nearly 4/5 of policies requiring two or more product steps.


Source: MMIT data as of Q4 2016

Trends:  Recent news related to narcotic pain treatment pose a threat to manufacturers. With physicians leading the charge as a part of FDA oversight to balance the effectiveness of narcotic pain treatments with the ongoing U.S. epidemic, this means much greater scrutiny on non-abuse-deterrent treatments. Patients, prescribers and manufacturers join together to support narcotic pain sufferers and put a spotlight on the value of these treatments, specifically focused on innovative abuse-deterrent products.

In the full Reality Check on narcotic pain treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on narcotic pain treatments with key findings on clinical characteristics, narcotic pain drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Branding & Marketing